Physician profile
Jose Rivera-Jimenez
NPI 1013165141
$1,138.57
in general payments reported to CMS, 2019-2025
17 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $80.86 · 2022: $35.06 · 2023: $30.67 · 2024: $179 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $180.73 | 2022-2025 | Amplatzer Amulet, Gallant |
| Boston Scientific Corporation | $170.47 | 2019-2025 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $160.14 | 2019-2022 | |
| Astellas Pharma US INC | $117.45 | 2019 | |
| Pfizer INC. | $71.25 | 2019 | |
| Kestra Medical Technology Services, INC. | $67.91 | 2024-2025 | Assure Wcd |
| Amgen INC. | $60.20 | 2019-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $56.18 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $47.32 | 2019-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.93 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $39.02 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.67 | 2023 | Jardiance |
| Medtronic Vascular, INC. | $30.20 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $22.88 | 2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $16.96 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16.11 | 2019 | |
| Cvrx, INC. | $11.15 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Rivera-Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.